BRIEF—Clinigen to run managed access program for Vyxeos in Europe

London-based pharmaceutical services group Clinigen has won a contract from Jazz Pharmaceuticals (Nasdaq: JAZZ) to run a managed access program for AML candidate Vyxeos (daunorubicin and cytarabine) outside the USA.

The program will see Vyxeos offered to certain newly-diagnosed patients in the UK, Ireland, Germany, and several other countries in Europe.

While approved in the USA, Vyxeos is not yet approved in Europe.

John Lagus, head of managed access at Clinigen, said: “There is a huge unmet need for adults with AML where treatment options to date have been very few. Vyxeos provides the first FDA approved chemotherapy treatment for patients with certain types of high-risk AML in more than 40 years.”